Search

Search Constraints

You searched for: Author/Creator Langkilde, Anna Maria

Search Results

41. Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. (29th July 2021)

42. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF. Issue 4 (26th January 2021)

43. FC 063DAPAGLIFLOZIN DECREASES ALBUMINURIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE WITH AND WITHOUT TYPE 2 DIABETES: INSIGHTS FROM THE DAPA-CKD TRIAL. (29th May 2021)

44. Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF. Issue 6 (20th April 2022)

45. Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF. Issue 13 (16th August 2022)

46. Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA‐HF. (22nd August 2022)

47. Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure: Is It Ever Too Late to Start a New Therapy?. (December 2020)

48. Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial. Issue 14 (6th March 2023)

49. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Issue 2 (7th February 2020)

50. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI 58. (29th December 2020)